Skip to main content

Research & Treatments

PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS ResearchTreatments

PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS

Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived xenograft (PDX) models to help researchers better understand why patients living…
laurabbook@gmail.com
November 22, 2018
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors ResearchTreatments

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an association between selection of EGFR T790M-negative but EGFR G724S-positive subclones and osimertinib resistance.…
laurabbook@gmail.com
November 22, 2018
J&J buys novel lung cancer drug from South Korea’s Yuhan ResearchTreatments

J&J buys novel lung cancer drug from South Korea’s Yuhan

*November 7, 2018* Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC). J&J’s pharma arm, Janssen, struck the deal with South Korea-based Yuhan and has agreed to pay $50m upfront to secure the licence. The move sent…
laurabbook@gmail.com
November 22, 2018
Bring Hope Home Research

Bring Hope Home

June 19th Living Room "Resistance to Targeted Therapy" Dr. Colin Blakely will be discussing all the questions about progression in your lung cancer and where to go and what to do. Dr. Blakely will be talking about what is happening in the research field from next generation therapies after progression from your 2nd…
cece
June 18, 2018
A Mix-and-Match Approach to Treating Non-Small-Cell Lung Cancer ResearchStories

A Mix-and-Match Approach to Treating Non-Small-Cell Lung Cancer

https://egfrcancer.org/wp-content/uploads/2018/03/Teri-Kennedy.jpg *** This article was first posted on www.curetoday.com*** During summer 2015, Teri Kennedy was at a yoga festival in Squaw Valley, California, when she started to wheeze and had trouble breathing. The inhaler her doctor gave her didn’t help. When the then 51-year-old from Sacramento returned home, she went…
cece
May 1, 2018